Display options
Cite
Bradbury S, Gittings D, Schenk S. Repeated exposure to MDMA and amphetamine: sensitization, cross-sensitization, and response to dopamine D₁- and D₂-like agonists. Psychopharmacology (Berl). 2012;223(4):389-99doi: 10.1007/s00213-012-2726-9.
Bradbury, S., Gittings, D., & Schenk, S. (2012). Repeated exposure to MDMA and amphetamine: sensitization, cross-sensitization, and response to dopamine D₁- and D₂-like agonists. Psychopharmacology, 223(4), 389-99. https://doi.org/10.1007/s00213-012-2726-9
Bradbury, Sarah, et al. "Repeated exposure to MDMA and amphetamine: sensitization, cross-sensitization, and response to dopamine D₁- and D₂-like agonists." Psychopharmacology vol. 223,4 (2012): 389-99. doi: https://doi.org/10.1007/s00213-012-2726-9
Bradbury S, Gittings D, Schenk S. Repeated exposure to MDMA and amphetamine: sensitization, cross-sensitization, and response to dopamine D₁- and D₂-like agonists. Psychopharmacology (Berl). 2012 Oct;223(4):389-99. doi: 10.1007/s00213-012-2726-9. Epub 2012 May 05. PMID: 22562523.
Copy Download .nbib Format: NLM
Share it on

Psychopharmacology (Berl). 2012 Oct;223(4):389-99. doi: 10.1007/s00213-012-2726-9. Epub 2012 May 05.

Repeated exposure to MDMA and amphetamine: sensitization, cross-sensitization, and response to dopamine D₁- and D₂-like agonists.

Psychopharmacology

Sarah Bradbury, David Gittings, Susan Schenk

Affiliations

  1. School of Psychology, Victoria University of Wellington, Wellington, New Zealand.

PMID: 22562523 DOI: 10.1007/s00213-012-2726-9

Abstract

RATIONALE: Acute exposure to (±) 3, 4-methylenedioxymethamphetamine (MDMA) produces hyperlocomotion that is preferentially expressed in the periphery of closed chambers. Following repeated administration, however, a sensitized hyperlocomotor response is preferentially expressed in the center of an activity box, so that the response resembles the more generalized activity that is produced by D-amphetamine (AMPH).

OBJECTIVES: The present study was designed to determine whether common neuroadaptations underlie the acute and sensitized responses to MDMA and AMPH.

METHODS: Rats were pretreated with five daily injections of MDMA (10.0 mg/kg), AMPH (2.0 mg/kg), or saline. Following a 2-day drug-free period, dose-response curves for hyperactivity produced by MDMA (2.5-10.0 mg/kg), AMPH (0.5-2.0 mg/kg), SKF-81297 (1.0-2.0 mg/kg), or quinpirole (0.25-1.0 mg/kg) were obtained.

RESULTS: Effects of MDMA and AMPH were increased by pretreatment with both drugs. The sensitized response following MDMA exposure was preferentially expressed in the center compartment, but, following AMPH pretreatment, the sensitized response was observed in both compartments. Cross-sensitization was unidirectional; AMPH pretreatment failed to sensitize to the effects of MDMA, but MDMA pretreatment sensitized to the effects of AMPH. MDMA and AMPH pretreatment produced marginal increases in the effects of SKF-81297. The response to quinpirole was, however, greater following MDMA, but not AMPH, pretreatment.

CONCLUSIONS: These data suggest that repeated MDMA exposure produces sensitization via a unique neurochemical effect.

References

  1. Behav Brain Res. 2005 May 28;160(2):304-11 - PubMed
  2. Brain Res Brain Res Rev. 1997 Oct;25(2):192-216 - PubMed
  3. Eur J Pharmacol. 1988 Apr 27;149(1-2):159-63 - PubMed
  4. J Pharmacol Exp Ther. 1999 Sep;290(3):965-73 - PubMed
  5. Curr Opin Pharmacol. 2007 Feb;7(1):69-76 - PubMed
  6. Psychopharmacology (Berl). 1999 Mar;143(1):39-46 - PubMed
  7. Neuropsychopharmacology. 2001 Jun;24(6):680-90 - PubMed
  8. Psychopharmacology (Berl). 1992;106(4):447-54 - PubMed
  9. Neuroreport. 2002 Apr 16;13(5):563-6 - PubMed
  10. J Neurosci. 1988 Aug;8(8):2788-803 - PubMed
  11. Psychopharmacology (Berl). 2004 Dec;177(1-2):100-10 - PubMed
  12. Neuropsychopharmacology. 2003 Aug;28(8):1422-32 - PubMed
  13. Nature. 1990 Sep 13;347(6289):146-51 - PubMed
  14. Eur J Neurosci. 2006 Jul;24(1):217-28 - PubMed
  15. J Pharm Pharmacol. 1974 Jan;26(1):30-3 - PubMed
  16. Eur J Pharmacol. 1976 Nov;40(1):45-56 - PubMed
  17. Prog Neuropsychopharmacol Biol Psychiatry. 1985;9(2):121-32 - PubMed
  18. Brain Res. 1989 Jun 26;490(2):255-67 - PubMed
  19. Eur J Pharmacol. 1989 Feb 28;161(2-3):151-7 - PubMed
  20. J Pharmacol Exp Ther. 2007 Jan;320(1):376-85 - PubMed
  21. Neuropsychopharmacology. 2005 Dec;30(12):2180-91 - PubMed
  22. J Pharmacol Exp Ther. 1987 Apr;241(1):338-45 - PubMed
  23. J Pharmacol Exp Ther. 1990 Aug;254(2):456-64 - PubMed
  24. Eur J Pharmacol. 1986 Aug 22;128(1-2):41-8 - PubMed
  25. Br J Pharmacol. 1994 Jul;112(3):873-80 - PubMed
  26. Psychopharmacology (Berl). 2004 May;173(3-4):326-36 - PubMed
  27. Pharmacol Biochem Behav. 1998 Jan;59(1):215-20 - PubMed
  28. Neuropsychopharmacology. 2002 Jan;26(1):18-26 - PubMed
  29. Addict Biol. 2010 Jul;15(3):289-98 - PubMed
  30. Behav Pharmacol. 2009 Dec;20(8):688-94 - PubMed
  31. Neurotoxicol Teratol. 2007 Jan-Feb;29(1):37-46 - PubMed
  32. Neuropsychopharmacology. 1996 Aug;15(2):116-24 - PubMed
  33. Pharmacol Biochem Behav. 1974 Mar-Apr;2(2):249-55 - PubMed
  34. Neuroreport. 1999 Oct 19;10(15):3131-6 - PubMed
  35. Neuropsychopharmacology. 2003 Nov;28(11):1889-902 - PubMed
  36. Psychopharmacology (Berl). 1989;99(1):40-7 - PubMed
  37. Psychopharmacology (Berl). 1991;105(1):107-12 - PubMed
  38. Neurosci Biobehav Rev. 2004 Jan;27(8):827-39 - PubMed
  39. Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):8155-9 - PubMed
  40. J Pharmacol Exp Ther. 1993 Feb;264(2):991-1001 - PubMed
  41. Physiol Behav. 2009 Mar 23;96(4-5):593-601 - PubMed
  42. Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1817-21 - PubMed
  43. Behav Brain Res. 1991 Nov 26;45(2):117-24 - PubMed
  44. Neuroreport. 1995 Jan 26;6(2):329-32 - PubMed
  45. Eur J Neurosci. 2008 Nov;28(9):1895-910 - PubMed
  46. Brain Res. 1975 Sep 5;94(3):507-22 - PubMed
  47. Behav Brain Res. 2008 May 16;189(1):52-64 - PubMed
  48. Prog Neurobiol. 1996 Aug;49(5):455-79 - PubMed
  49. Neuroscience. 2009 May 5;160(2):264-74 - PubMed
  50. Pharmacol Biochem Behav. 1997 Dec;58(4):955-60 - PubMed
  51. Psychopharmacology (Berl). 2005 Apr;178(4):505-13 - PubMed
  52. Brain Res. 2003 Dec 24;994(2):203-15 - PubMed
  53. Neuropsychopharmacology. 2006 Nov;31(11):2349-58 - PubMed
  54. Nature. 1976 Apr 22;260(5553):731-2 - PubMed
  55. Neuropsychopharmacology. 1998 Jun;18(6):469-79 - PubMed
  56. Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jun;29(5):648-57 - PubMed
  57. Int J Neuropsychopharmacol. 2010 Nov;13(10):1315-27 - PubMed
  58. Psychopharmacology (Berl). 1999 Apr;143(3):244-53 - PubMed
  59. Pharmacol Biochem Behav. 1993 Jul;45(3):647-53 - PubMed
  60. Behav Pharmacol. 2011 Dec;22(8):847-50 - PubMed
  61. Psychopharmacology (Berl). 2000 Aug;151(2-3):99-120 - PubMed
  62. Behav Brain Funct. 2006 Jan 04;2:1 - PubMed
  63. Psychopharmacology (Berl). 1986;90(2):247-52 - PubMed
  64. Neuropsychopharmacology. 1993 May;8(3):201-11 - PubMed
  65. Psychopharmacology (Berl). 1990;102(4):459-64 - PubMed
  66. Pharmacol Biochem Behav. 1990 Aug;36(4):989-91 - PubMed
  67. Psychopharmacologia. 1969;14(4):299-304 - PubMed
  68. J Pharmacol Exp Ther. 2000 Dec;295(3):1223-31 - PubMed
  69. J Pharmacol Exp Ther. 1996 Oct;279(1):277-83 - PubMed
  70. Eur J Pharmacol. 1987 Apr 7;136(1):81-8 - PubMed
  71. Neuropharmacology. 2004 Feb;46(2):202-10 - PubMed
  72. Pharmacol Biochem Behav. 2004 Apr;77(4):745-50 - PubMed
  73. Brain Res Brain Res Rev. 1993 Sep-Dec;18(3):247-91 - PubMed
  74. Eur J Pharmacol. 2001 Dec 14;433(1):91-9 - PubMed
  75. Eur J Pharmacol. 2000 Nov 10;408(1):41-9 - PubMed
  76. Behav Pharmacol. 1989;1(3):209-220 - PubMed

Substances

MeSH terms

Publication Types